{"id":232791051,"title":"#分享 醫材管理法三讀通過，Apple Watch ECG 功能開放有望？","content":"https://megapx-assets.dcard.tw/images/1119f65b-c7fd-4a88-a8e6-e4cdff919b3d/1280.jpeg\nApple Watch 從第四代 Series 4 便推出心電圖（ECG）功能，然而因為台灣醫材法規的限制，這項功能在台灣並未開放，不過隨著立法院 13 日三讀通過醫療器材管理法草案，將醫療器材管理由「藥事法」中抽離，許多人都看好 ECG 功能將有望獲得開放，但情況究竟是如何呢？\n\n\n台灣現行醫材管理規定主要來自藥事法，將其中所稱「藥物」包含「藥品」及「醫療器材」進行規範，然而醫材畢竟與藥品管理上有諸多不同，隨著近年科技及醫材產業蓬勃發展，智慧型穿戴裝置陸續出現，藥事法明顯已經難以滿足醫療器材管理需求。\n\n為完善醫材管理制度，衛生署自 103 年起便開始規劃評估專法架構，並於 104 年草擬法規，在經過數年等待後，包含 85 條條文的管理法草案近日也終於在立法院三讀通過。\n\n據了解，條文除了強化上市醫材安全監督管理、加強醫材臨床試驗之規範，為鼓勵產業研發及產品創新，同時也將從事醫材設計並以其名義上市者納入醫材製造業，並提供部分「低風險」醫材由查驗登記改採電子化登錄，並能以年度申報延續登錄效力。\n\n依醫材管理辦法規定，醫材可分為 17 大類、3 種風險程度，其中心電圖管理系統（ECG management system）被歸類於「心臟血管醫學」的第一等級（低風險），但相關的品項如心臟監視器（含心動數計和心率警示器）、心律不整檢測器和警示器都被歸類於第二等級（中風險），是否真能受惠於新法鬆綁、免於通過漫長的 TFDA 認證還有待觀望。\nhttps://megapx-assets.dcard.tw/images/9f08fc84-6fcf-4e50-b8d7-d27838cfe8be/full.jpeg\n（Source：食藥管理署）\n\n儘管如此，從食藥署公布的法案懶人包中，關於醫材法亮點處仍可見「加速創新醫材產品上市」、「促進多元商務發展」等說法，以此來看，ECG 功能的開放或許仍有機會值得期待。\n（首圖來源：蘋果）\n\nhttps://technews.tw/2019/12/30/apple-watch-ecg-features-may-be-coming/\n\n請問大家手中的Apple Watch都有支援ECG功能嗎？","excerpt":"Apple Watch 從第四代 Series 4 便推出心電圖（ECG）功能，然而因為台灣醫材法規的限制，這項功能在台灣並未開放，不過隨著立法院 13 日三讀通過醫療器材管理法草案，將醫療器材管理由","anonymousSchool":false,"anonymousDepartment":true,"pinned":false,"forumId":"42bfdc63-8601-4e87-b53c-53d831caa2cf","replyId":null,"createdAt":"2019-12-30T13:06:48.777Z","updatedAt":"2019-12-30T13:13:43.154Z","commentCount":2,"likeCount":11,"tags":[],"topics":["Apple","醫材","AppleWatch","ECG","功能"],"supportedReactions":null,"withNickname":false,"reportReason":"","hiddenByAuthor":false,"meta":{"layout":"classic"},"forumName":"Apple","forumAlias":"apple","school":"國立空中大學","replyTitle":null,"gender":"M","personaSubscriptable":null,"reactions":[{"id":"286f599c-f86a-4932-82f0-f5a06f1eca03","count":9},{"id":"aa0d425f-d530-4478-9a77-fe3aedc79eea","count":2}],"hidden":false,"customStyle":null,"isSuspiciousAccount":false,"layout":"classic","withImages":true,"withVideos":false,"media":[{"url":"https://megapx-assets.dcard.tw/images/1119f65b-c7fd-4a88-a8e6-e4cdff919b3d/1280.jpeg"},{"url":"https://megapx-assets.dcard.tw/images/9f08fc84-6fcf-4e50-b8d7-d27838cfe8be/full.jpeg"}],"reportReasonText":"","mediaMeta":[{"id":"cb5a1809-64f3-4fcb-8dd3-0948f8a0fc5d","url":"https://megapx-assets.dcard.tw/images/1119f65b-c7fd-4a88-a8e6-e4cdff919b3d/640.jpeg","normalizedUrl":"https://megapx-assets.dcard.tw/images/1119f65b-c7fd-4a88-a8e6-e4cdff919b3d/640.jpeg","thumbnail":"https://megapx-assets.dcard.tw/images/1119f65b-c7fd-4a88-a8e6-e4cdff919b3d/640.jpeg","type":"image/thumbnail","tags":["ANNOTATED"],"createdAt":"2019-12-30T13:06:48.777Z","updatedAt":"2019-12-30T13:13:43.154Z","width":640,"height":426},{"id":"cb5a1809-64f3-4fcb-8dd3-0948f8a0fc5d","url":"https://megapx-assets.dcard.tw/images/1119f65b-c7fd-4a88-a8e6-e4cdff919b3d/1280.jpeg","normalizedUrl":"https://megapx.dcard.tw/v1/images/1119f65b-c7fd-4a88-a8e6-e4cdff919b3d","thumbnail":"https://megapx-assets.dcard.tw/images/1119f65b-c7fd-4a88-a8e6-e4cdff919b3d/640.jpeg","type":"image/megapx","tags":["ANNOTATED"],"createdAt":"2019-12-30T13:06:48.777Z","updatedAt":"2019-12-30T13:13:43.154Z","width":1592,"height":1060},{"id":"dcc2b7b8-4fe1-465c-98b7-5710ff8891f7","url":"https://megapx-assets.dcard.tw/images/9f08fc84-6fcf-4e50-b8d7-d27838cfe8be/full.jpeg","normalizedUrl":"https://megapx.dcard.tw/v1/images/9f08fc84-6fcf-4e50-b8d7-d27838cfe8be","thumbnail":"https://megapx-assets.dcard.tw/images/9f08fc84-6fcf-4e50-b8d7-d27838cfe8be/320.jpeg","type":"image/megapx","tags":["ANNOTATED"],"createdAt":"2019-12-30T13:06:48.777Z","updatedAt":"2019-12-30T13:13:43.154Z","width":640,"height":364}],"postAvatar":""}